Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Excellent results out this morning and actually doing more work than I expected in Lockdown. Will soon be back to normal trading. Also I expect that profits could well be up this year as what happens when less work is generally available for workmen and suppliers is that their prices drop to contractors like MGNS thus improving profits or in MGNS case making up for any shortfall in tutnover. Alsos they have a huge future order book and with lockdown easing this weekend all should be back to normal soon. Not a lot of shares in free float so I would get in quick if your keen as could soon get bavk to normal share price of about 1800
UP 20% already on level 2-this is going to rocket
Synairgen plc Extension of clinical study in COVID-19 patients
30/04/2020 12:09pm
UK Regulatory (RNS & others)
Synairgen (LSE:SNG)
Intraday Stock Chart
Thursday 30 April 2020
Click Here for more Synairgen Charts.
TIDMSNG
RNS Number : 5139L
Synairgen plc
30 April 2020
Press release
Synairgen plc
('Synairgen' or the 'Company')
Approval received to extend SG016 clinical study of SNG001 in COVID-19 to initiate patients in the home environment
Southampton, UK - 30 April 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it has received approvals to extend the SG016 trial to patients with SARS-CoV-2 in the home environment. The objective is to initiate dosing with SNG001 (or placebo) earlier in the infection cycle, and before severe lower respiratory tract symptoms have developed. In due course, details of the design, implementation and timing of this novel study will be disclosed more fully.
The treatment of patients in the hospital setting in the SG016 study is progressing well, with more than 75 patients out of the target 100 now dosed with Synairgen's wholly-owned drug SNG001 or placebo. Results from this part of the study are still expected in June 2020.
Tipped in the Mail on Sunday, in their Stocks to Watch column:
Https://www.thisismoney.co.uk/money/markets/article-8257007/STOCK-WATCH-Fears-grow-BPs-Alaska-sale-prove-half-baked.html
"Westminster Group
Former Tory MP Sir Tony Baldry's aptly named security company, Westminster Group, is due to reveal record first-quarter results on Thursday, but the share price has still suffered in recent weeks from the coronavirus pandemic.
That's because it provides security services to Freetown International Airport in Sierra Leone, which is shut because of the outbreak.
However, the company has seen a surge in demand for its fever screening equipment during the crisis.
I hear Westminster is poised to launch a marketing campaign that could help boost sales of its testing kit further and – investors will hope – boost its shares, too."
£3.60 ON SUCCESS
Finncap morning note from 31 MAR 20
Synairgen
First COVID-19 patient dosed
Synairgen confirmed that it has commenced dosing patients in its Phase II trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients, the first patient having been enrolled at University Hospital Southampton. A further six sites have been initiated, which are expected to start dosing in the coming days.
These sites, together with potentially three more, should enable the company to complete enrolment during April. Clearly this is a positive development and testament to the efforts of Synairgen, regulators and clinicians to help COVID-19
patients, with results expected during Q2 2020 that will determine the next action points. We reiterate our 120p target price with the prospect that this would rise by up to 240p on a positive outcome.
• First patient dosed.
The first patient has been dosed at the initial trial site at University Hospital Southampton NHS Foundation Trust. Synairgen has initiated a further 6 trial sites which are expected to start dosing in the coming days, having
previously indicated that it expects c.10 sites to participate in the trial.
• Clinical trial summary.
It is a double-blind placebo-controlled Phase II trial in hospitalised COVID-19 patients (not yet on ventilator) that will enrol 100 patients. As indicated in our report of 26 March, we think that results could be generated during Q2 2020, given an estimated two weeks to complete enrolment, two weeks to complete dosing, with a further 2-4 weeks of follow-up followed by analysis of data.
•Valuation.
We reiterate our rNPV-based target price of 120p, of which c.80p relates to the use of SNG001 in COVID-19 disease. The successful completion of the Phase II study (SG016) would imply a rNPV of as much as c.£475m or a c.360p target price – suggesting a c.£360m (240p) uplift on the current estimated NPV.
New shares-trading
Admission of the Firm Placing Shares and Total Voting Rights
Application has been made to the London Stock Exchange for the 10,943,295 Firm Placing Shares to be admitted to trading on AIM ("Firm Admission") and it is expected that Firm Admission will become effective and trading will commence in the Firm Placing Shares at 8.00 a.m. on 30 March 2020.
As you can see from RNS 26 March new shares have been on market since 30 March so whats this all about them only being available shortly ?
This looks very interesting apparently Russia Saudis and US to be in talks to lower production all round to get much higher oil price.
In fact could double the oil price if a deal can be done as they all want higher prices.
Would be geat for Hurricane.
With vacines not being available for at least a year yet Synairgen could be a real winner for treating people. Possibly the only treatment available. Also with the fact its an inhaler people can use it themselves so no need for a doctor or injection.With trials now going full steam ahead results should be out in a month or two.
Price drop today lets you get in at bargain prices
My figures are as follows
iNCOME is 20,000 barrels a day x 365 days a year that's 7,800,000 barrels a year.
-At $50 per barrel that's $390 ,000,000 per annum
Say the cost is $20 per barrel that's a net profit of $219,000,000 per annum
As regards cost per barrel I think original estimates of cost were based on a much lower output so as output increases the cost per barrel will decrease as a lot of the costs will be fixed cost so as production increases cost per barrel decrease.
The market value of Hurricane at today's share price is £288 Million or $370 million
If they stopped exploration and kept pumping the share price would certainly be a lot lot higher
However as it is the share price is way undervalued in my view.
I also expect that at the march capital day we will be told that the current well tests have shown that they can even pump at a higher rate.
Any comment on my figures or view anyone?
Whilst you may think this rise is just a pump the facts are that Westminster have reported 5 contracts for fever detection equipment to date THIS YEAR and some of those will quite big contracts. These are the orders received to date from around the world and you can be sure there will be more to come. Not only does this provide some great turnover for Westminster but also it brings the companies visibilty and credibility to a much higher level of awareness. This should enable them to really get a foot into the managed services and security services opportunities worldwide and should be the start of a really rapid rise in their turnover and profitability . The company at this stage is very small with a market capitilisation of only £17 million. When the TEMA contract is signed shortly and more contracts are announced todays share price will be left far behind. My target is at least 30p but could be much higher if they keep winning contracts. Don't be tempted to take short term profits, you could be very sorry
It is really amazing that the Dermasys gel alone has the intended effect. I wish they had discovered this earlier as it would have saved a lot of costs. However here we are with a brilliant product that is drug free and does the job. I don't think things could have turned out better and has really enlarged the available market place especially as it seems it can be used in conjuction with other products like viagra. In fact the commercial opportunity seems much larger.
If they get the regulatory approvals and the 20 year patents the share price price will certainly be higher than today .So in my view today's price maybe the last chance for you to get in cheap
More clarity may emerge when Hurricane publishes additional data at its capital markets day on 25 March, which analysts at Arden Partners think could be significant for visibility.
They said: “The market appears to have sold off in the run up to this, as well as in response to the end of the 2019 drilling programme.
“Our view remains that while there is a binary risk from the Lancaster conclusions, the upside potential due to the size of the field remains significant, all the more so at current share price levels.”
While acknowledging the risk, the team at Arden think there's potential for shares to reach 90p. They made no change to their forecasts today, adding that it would be a positive for Hurricane if got permission for Lincoln Crestal to remain suspended for use at a later date.
Analysts at Stifel have a target price of 100p, adding that additional Lancaster production drilling represented the “highest and best use of capital”.